Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

PURPOSE: Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first reported in 2005. One of these reports, the joint analysis of North Central Cancer Treatm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Perez, Edith A., Romond, Edward H., Suman, Vera J., Jeong, Jong-Hyeon, Sledge, George, Geyer, Charles E., Martino, Silvana, Rastogi, Priya, Gralow, Julie, Swain, Sandra M., Winer, Eric P., Colon-Otero, Gerardo, Davidson, Nancy E., Mamounas, Eleftherios, Zujewski, Jo Anne, Wolmark, Norman
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2014
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226805/
https://ncbi.nlm.nih.gov/pubmed/25332249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.55.5730
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi